CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

51.42 -0.34 (-0.66%)

Streaming Delayed Price Updated: 9:40 AM EDT, Apr 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

35 36 Next >

The 3 Best Growth Stocks to Buy in the Biotech Sector ↗

March 29, 2023

These three biotech growth stocks are brimming with potential and could offer massive upside for patient investors.

Via InvestorPlace

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures ↗

March 29, 2023

For those that can handle the heat, these biotech stocks to buy undergird some of the most powerful innovations in medicine.

Via InvestorPlace

Why Bluebird Bio Shares Are Plunging Today ↗

March 29, 2023

Via Benzinga

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

March 27, 2023

From Vertex Pharmaceuticals Incorporated

Via Business Wire

Could This Stock Become the Tesla of Its Industry? ↗

March 25, 2023

It's in a race to a multi-billion dollar market.

Via The Motley Fool

Expert Ratings for CRISPR Therapeutics ↗

March 21, 2023

Via Benzinga

Expert Ratings for CRISPR Therapeutics ↗

February 27, 2023

Via Benzinga

Looking Into CRISPR Therapeutics's Return On Invested Capital ↗

February 22, 2023

Via Benzinga

Could CRISPR Therapeutics Become the Next Moderna? ↗

March 27, 2023

Both companies use cutting-edge technology.

Via The Motley Fool

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗

March 25, 2023

Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it.

Via InvestorPlace

3 Simple Ways to Supercharge Your Biopharma Investing Using Artificial Intelligence ↗

March 24, 2023

Your stock screening and research process will never be the same.

Via The Motley Fool

This Cathie Wood Stock Could Nearly Double, According to Wall Street ↗

March 23, 2023

If the stock market continues to rally, this biotech could benefit.

Via The Motley Fool

Thinking of Buying Biotech Stocks? Do These 3 Things First ↗

March 22, 2023

It's better to plan ahead than to get caught by surprise.

Via The Motley Fool

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗

March 21, 2023

Via Benzinga

3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time ↗

March 18, 2023

For investors betting on healthcare, look for these three companies to provide the treatments of tomorrow.

Via InvestorPlace

3 Beaten-Down Stocks That Could Soar This Year ↗

March 18, 2023

These stocks could enjoy big rebounds in 2023.

Via The Motley Fool

2 Top Biotech Stocks to Buy for the Long Haul ↗

March 15, 2023

These companies have what it takes to grow their revenues -- and their share prices -- over time.

Via The Motley Fool

If You Invested $10,000 in CRISPR Therapeutics In 2020, This Is How Much You Would Have Today ↗

March 10, 2023

The stock has been on a wild ride over the past few years.

Via The Motley Fool

Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold ↗

March 09, 2023

Get in on CRISPR Therapeutics before it gets expensive.

Via The Motley Fool

2 Healthcare Stocks That Could Help Make You a Fortune ↗

March 08, 2023

These companies also happen to be a bargain right now.

Via The Motley Fool

7 Cathie Wood Stocks for Your March Buy List ↗

March 07, 2023

These top Cathie Wood stocks are just now attempting to pivot higher after a miserable outing for much of 2022.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 ↗

March 07, 2023

Via Benzinga

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing ↗

March 06, 2023

CRISPR Therapeutics, Beam Therapeutics and Vertex Pharmaceuticals are three CRISPR gene editing stocks you won't want to miss out on.

Via InvestorPlace

Better Growth Stock: Moderna vs. CRISPR Therapeutics ↗

March 05, 2023

Both stocks are ripe for a rebound.

Via The Motley Fool

3 Things About CRISPR Therapeutics That Smart Investors Know ↗

March 04, 2023

Institutional investors might be on to something.

Via The Motley Fool

3 Game-Changing Stocks to Buy in March ↗

March 04, 2023

Innovation is in these companies' DNA.

Via The Motley Fool

2 Soaring Stocks to Buy and Hold Through 2023 and Beyond ↗

March 03, 2023

Investors are bidding up shares of these companies, and there are good reasons for doing so.

Via The Motley Fool

10 Best Stocks to Buy in March 2023 ↗

March 01, 2023

These diversified growth stocks could add rocket fuel to your long-term investment portfolio.

Via The Motley Fool

Here's How Much You Can Make From Investing Your Tax Return Every Year ↗

February 27, 2023

Doing this can strengthen your retirement plan.

Via The Motley Fool

Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗

February 22, 2023

The two clinical-stage gene-editing companies have good long-term prospects.

Via The Motley Fool

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.